Katsuhiro Miura

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Journal of pharmaceutical health care and sciences

Biomedicines

International journal of clinical pharmacy

Hematological oncology

Nihon University School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Nihon University School of Medicine

Japan

Assistant Professor :: Division of Hematology and Rheumatology, Department of Medicine

Publications

Katsuhiro Miura, Haruna Nishimaki-Watanabe, Hiromichi Takahashi, Masaru Nakagawa, Shimon Otake, Takashi Hamada, Takashi Koike, Kazuhide Iizuka, Yuuichi Takeuchi, Kazuya Kurihara, Toshihide Endo, Shun Ito, Hironao Nukariya, Takahiro Namiki, Yoshiyuki Hayashi, Hideki Nakamura
TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly. Biomedicines 12 (6) (2024)
Katsuhiro Miura, Haruna Nishimaki-Watanabe, Hiromichi Takahashi, Masaru Nakagawa, Shimon Otake, Takashi Hamada, Takashi Koike, Kazuhide Iizuka, Yuuichi Takeuchi, Kazuya Kurihara, Toshihide Endo, Shun Ito, Hironao Nukariya, Takahiro Namiki, Yoshiyuki Hayashi, Hideki Nakamura
TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly. Biomedicines 12 (6) (2024)
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka
Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. Journal of pharmaceutical health care and sciences 9 (1) (2023)
Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience. Journal of pharmaceutical health care and sciences 9 (1) (2023)
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka
Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. Journal of pharmaceutical health care and sciences 9 (1) (2023)
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka
Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. Journal of pharmaceutical health care and sciences 9 (1) (2023)
Takashi Koike, Katsuhiro Miura, Yoshihiro Hatta, Hideki Nakamura, Yoko Hirabayashi, Miyuki Yuda, Tomonori Harada, Shuichi Hirai, Isao Tsuboi, Shin Aizawa
Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis. Annals of hematology (2023)
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka
Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. Journal of pharmaceutical health care and sciences 9 (1) (2023)
Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Yoshihito Uchino, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma. Expert review of anticancer therapy 22 (6) (2022)
Hiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, Haruna Nishimaki, Shun Ito, Hironao Nukariya, Kazuya Kurihara, Toshihide Endo, Takashi Koike, Takashi Hamada, Kazuhide Iizuka, Shimon Ohatake, Noriyoshi Iriyama, Tomohiro Nakayama, Shinobu Masuda, Yoshihiro Hatta, Hideki Nakamura
Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study. Hematological oncology (2022)
Hiromichi Takahashi, Haruna Nishimaki, Yoko Nakanishi, Takashi Hamada, Masaru Nakagawa, Kazuhide Iizuka, Yoshihito Uchino, Noriyoshi Iriyama, Katsuhiro Miura, Tomohiro Nakayama, Shinobu Masuda, Yoshihiro Hatta, Hideki Nakamura
Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: A single institution's experience. EJHaem 3 (2) (2022)
Noriyoshi Iriyama, Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Takashi Hamada, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tomohiro Nakayama, Yoshihiro Hatta, Hideki Nakamura
Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience. Leukemia & lymphoma (2022)
Daisuke Tsutsumi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Shinya Tsuboi, Susumu Otsuka, Yoshihiro Hatta, Yukinaga Kishikawa
A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. International journal of clinical pharmacy (2021)
Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. Hematological oncology 39 (1) (2020)
Tatsuya Hayama, Kenichi Sakurai, Katsuhiro Miura, Shinsaku Washinosu, Shinya Tsuboi, Akihiro Uchiike, Yoshikazu Yoshida, Masami Takei
Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. International journal of clinical pharmacy 40 (5) (2018)

Katsuhiro Miura.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Katsuhiro Miura